Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Renal Cell Carcinoma
Drug:
Aybintio (bevacizumab biosimilar)
(
VEGF-A inhibitor
) +
Pegasys (pegylated interferon α -2a)
(
IFNα stimulant
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
European Medicines Agency
Excerpt:
Aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login